Results 171 to 180 of about 33,833 (238)

Cost-effectiveness of BPaL/BPaLM as compared to mixed standard of care bedaquiline containing regimen for MDR/RR-TB. [PDF]

Indian J Med Res
Muniyandi M, Nagarajan K, Chelvanayagam K, Rajsekar K, Tyagi K, Padmapriyadarsini C.   +5 more
europepmc   +1 more source

Structural and functional analysis of the <i>Mycobacterium tuberculosis</i> MmpS5L5 efflux pump presages increased bedaquiline resistance. [PDF]

Proc Natl Acad Sci U S A
Fountain AJ, Böhning J, McLaughlin SH, Morgan TE, Edelstein PH, Troll M, Lamers MH, Bharat TAM, Luisi BF, Ramakrishnan L.   +9 more
europepmc   +1 more source

Deconvoluting drug interactions using <i>M. tuberculosis</i> physiologic processes: transcriptional disaggregation of the BPaL regimen <i>in vivo</i>. [PDF]

Antimicrob Agents Chemother
Wynn EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, Hendrix J, Voskuil MI, Obregón-Henao A, Lyons MA, Robertson GT, Moore CM, Walter ND.   +10 more
europepmc   +1 more source

Plasma and CSF pharmacokinetic characteristics of second-line anti-tuberculosis drugs in a patient with multidrug-resistant tuberculous meningitis. [PDF]

BMC Infect Dis
Gao J, Cao J, Li J, Pan X, Wang H, Cai X, Chen Y.   +6 more
europepmc   +1 more source

Novel Pharmacological Approaches for Multidrug-Resistant Tuberculosis: Review. [PDF]

Adv Pharmacol Pharm Sci
Ayenew KD, Habteweld HA, Tsige AW, Bizu YS.   +3 more
europepmc   +1 more source

New drugs for the management of tuberculosis. [PDF]

Curr Opin Infect Dis
Cross GB.
europepmc   +1 more source

Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database. [PDF]

BMJ Open
Zhao L, Zeng L, Qian Y, Zhao W, Xie R.
europepmc   +1 more source

Relapse and Emergent Resistance With Novel Short-Course Regimens for Multidrug-Resistant Tuberculosis, United States, 2022-2024. [PDF]

Open Forum Infect Dis
Liang R, Brust JCM, Reed C, Escuyer V, Armstrong DT, Parrish N, Valois P, Rowlinson MC, Marinova-Petkova A, Bisson GP, Labuda SM, Colon-Semidey A, Haley CA, Ashkin D, Peloquin CA, Lardizabal A, Patrawalla A, Cuenca A, Haas MK, Brostrom R, Mbakwem C, Schechter MC, Ray SM, Cummins J, Cahill B, Arn K, Chen LL, Wilson JW, Goswami ND.   +28 more
europepmc   +1 more source

Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting [PDF]

core   +1 more source